Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock

Cathie Wood’s ARK ETFs have published their daily trades for Tuesday, March 25th, 2025, revealing a series of strategic moves in the biotech and tech sectors. Leading the pack in dollar value was the purchase of Beam Therapeutics Inc (NASDAQ:BEAM) shares, with ARK’s flagship innovation ETF ARKK and its genomics-focused ARKG ETF acquiring a combined 246,658 shares valued at approximately $5.92 million. This marks another significant investment in Beam, following consistent buying patterns observed over the past week.

ARK’s interest in space exploration and robotics was evident with the acquisition of 153,056 shares of Intuitive Machines Inc (NASDAQ:LUNR), distributed between its ARKQ and ARKX (NYSE:ARKX) ETFs, amounting to a total investment of $1.41 million. This purchase adds to their holdings from the previous day, indicating a growing position in the lunar exploration company.

The fund also increased its stake in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) by purchasing 205,226 shares across ARKK and ARKG, totaling around $1.39 million. This continues a trend of accumulating RXRX shares, as seen in recent trade reports.

In addition, ARK bolstered its position in Pacific Biosciences of California Inc (NASDAQ:PACB) by buying 415,398 shares through ARKK, investing over half a million dollars. This move comes just after a smaller purchase on the previous trading day, signaling sustained confidence in the gene sequencing company.

On the selling side, ARK divested 70,995 shares of Illumina Inc (NASDAQ:ILMN) from both ARKK and ARKG ETFs, and 66,244 shares of UiPath Inc (NYSE:PATH) spread across ARKK and ARKQ. These sales come amidst a backdrop of previous trades where ARK reduced its positions in both companies.

Furthermore, ARK sold 36,131 shares of Repare Therapeutics Inc (NASDAQ:RPTX) solely through its ARKG ETF, a continuation of its selling trend in the pharmaceutical company over the past week.

Lastly, ARK continued to build its stake in Absci Corp (NASDAQ:ABSI) by purchasing 70,081 shares through ARKG, with a total dollar value of $217,251. This follows a consistent pattern of buying in recent days, suggesting a focused accumulation strategy for the synthetic biology company.

Investors and market watchers keenly observe ARK’s daily trades, as Cathie Wood’s ETFs are known for their active management and focus on disruptive innovation. The trades provide insights into the fund’s strategic shifts and are a barometer for sentiment in cutting-edge sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.